on agreement with AstraZeneca, along with MedImmune, its global biologics research and development arm, to accelerate and broaden the development of Innate Pharma's proprietary anti-NKG2A antibody, IPH2201, including in combination with MEDI4736, an anti-PD-L1 immune checkpoint inhibitor developed by MedImmune. Currently in Phase II development, IPH2201 is a potential first-in-class humanized IgG4 antibody. In April 2015, AstraZeneca and MedImmune announced that they have entered into an exclusive collaboration agreement with Celgene Corporation, for the development and commercialisation of MEDI4736 across a range of blood cancers including non-Hodgkin's lymphoma, myelodysplastic syndromes and multiple myeloma. In May 2015, AstraZeneca plc and MedImmune, have entered into a collaboration with Innate Pharma SA to develop Innate's anti-NKG2A antibody, IPH2201, including in combination with MEDI4736, an anti-PD-L1 immune checkpoint inhibitor developed by MedImmune. History The company was founded 1992. It was incorporated in England and Wales in 1992 under the Companies Act 1985. The company was formerly known as Zeneca Group PLC and changed its name to AstraZeneca PLC in 1999.
astrazeneca plc (AZNCF:OTC US)
2 Kingdom Street
London, W2 6BD
Phone: 44 20 7604 8000
Fax: 44 20 7604 8151www.astrazeneca.com
|BASF SE||€86.86 EUR||+1.15|
|Biogen Inc||$385.80 USD||-0.42|
|Celgene Corp||$107.54 USD||-2.36|
|Eli Lilly & Co||$71.91 USD||-1.14|
|Valeant Pharmaceuticals International Inc||C$264.60 CAD||-5.09|
|View Industry Companies|
Sponsored Financial Commentaries
To contact ASTRAZENECA PLC, please visit www.astrazeneca.com. Company data is provided by Capital IQ. Please use this form to report any data issues.